CoChat

Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue

Open access
Catenacci, Daniel V. T., Liao, Wei-Li, Thyparambil, Sheeno, Henderson, Les, Xu, Peng, Zhao, Lei, Rambo, Brittany, Hart, John, Xiao, Shu-Yuan, Bengali, Kathleen, Uzzell, Jamar, Darfler, Marlene, Krizman, David B., Cecchi, Fabiola, Bottaro, Donald P., Karrison, Theodore, Veenstra, Timothy D., Hembrough, Todd, Burrows, Jon · 2014 · PLoS ONE
Cited by 53

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Overexpression of Met tyrosine kinase receptor is associated with poor prognosis. Overexpression, and particularly MET amplification, are predictive of response to Met-specific therapy in preclinical models. Immunohistochemistry (IHC) of formalin-fixed paraffin-embedded (FFPE) tissues is currently used to select for 'high Met' expressing tumors for Met inhibitor trials. IHC suffers from antibody non-specificity, lack of quantitative resolution, and, when quantifying multiple proteins, inefficient use of scarce tissue. METHODS: After describing the development of the Liquid-Tissue-Selected Reaction Monitoring-mass spectrometry (LT-SRM-MS) Met assay, we evaluated the expression level of Met in 130 FFPE gastroesophageal cancer (GEC) tissues. We assessed the correlation of SRM Met expression to IHC and mean MET gene copy number (GCN)/nucleus or MET/CEP7 ratio by fluorescence in situ hybridization (FISH). RESULTS: Proteomic mapping of recombinant Met identified 418TEFTTALQR426 as the optimal SRM peptide. Limits of detection (LOD) and quantitation (LOQ) for this peptide were 150 and 200 amol/µg tumor protein, respectively. The assay demonstrated excellent precision and temporal stability of measurements in serial sections analyzed one year apart. Expression levels of 130 GEC tissues ranged (<150 amol/µg to 4669.5 amol/µg. High correlation was observed between SRM Met expression and both MET GCN and MET/CEP7 ratio as determined by FISH (n = 30; R2 = 0.898). IHC did not correlate well with SRM (n = 44; R2 = 0.537) nor FISH GCN (n = 31; R2 = 0.509). A Met SRM level of ≥1500 amol/µg was 100% sensitive (95% CI 0.69-1) and 100% specific (95% CI 0.92-1) for MET amplification. CONCLUSIONS: The Met SRM assay measured the absolute Met levels in clinical tissues with high precision. Compared to IHC, SRM provided a quantitative and linear measurement of Met expression, reliably distinguishing between non-amplified and amplified MET tumors. These results demonstrate a novel clinical tool for efficient tumor expression profiling, potentially leading to better informed therapeutic decisions for patients with GEC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0100586

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

    Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059 · cited 1×

    “Specifically, MET gene amplification and consequent overexpression is an ‘oncogenic driver’ in a subset (,5%) of gastric and esophageal adenocarcinomas [4,11–14], while MET mutations have been rarely reported in various hereditary and sporadic cancers including gastroesophageal adenocarcinomas (GEC) [15].”
    Background

Show all 1 references

Research works printed but not linked: 48

  1. S Peters, 2012, MET: a promising anticancer therapeutic target, Nat Rev Clin Oncol, 9, 314, 10.1038/nrclinonc.2012.71 · DOI · Paper page
  2. F Cecchi, 2012, Targeting the HGF/Met signaling pathway in cancer therapy, Expert Opin Ther Targets, 16, 553, 10.1517/14728222.2012.680957 · DOI · Paper page
  3. L Trusolino, 2010, MET signalling: principles and functions in development, organ regeneration and cancer, Nat Rev Mol Cell Biol, 11, 834, 10.1038/nrm3012 · DOI · Paper page
  4. DV Catenacci, 2011, RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma, Cancer Biol Ther, 12, 9, 10.4161/cbt.12.1.15747 · DOI
  5. F Graziano, 2011, Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer, J Clin Oncol, 29, 4789, 10.1200/JCO.2011.36.7706 · DOI · Paper page
  6. X Liu, 2008, Targeting the Met signaling pathway for cancer therapy, Expert Opin Investig Drugs, 17, 997, 10.1517/13543784.17.7.997 · DOI
  7. KP Raghav, 2012, cMET and phospho-cMET protein levels in breast cancers and survival outcomes, Clin Cancer Res, 18, 2269, 10.1158/1078-0432.CCR-11-2830 · DOI
  8. AA Sadiq, 2013, MET as a possible target for non-small-cell lung cancer, J Clin Oncol, 31, 1089, 10.1200/JCO.2012.43.9422 · DOI · Paper page
  9. N Sharma, 2011, In the clinic: ongoing clinical trials evaluating Met-inhibiting drugs, Ther Adv Med Oncol, 3, S37, 10.1177/1758834011423403 · DOI
  10. E Gherardi, 2012, Targeting MET in cancer: rationale and progress, Nat Rev Cancer, 12, 89, 10.1038/nrc3205 · DOI · Paper page
  11. JA Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478 · DOI · Paper page
  12. GA Smolen, 2006, Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752, Proc Natl Acad Sci U S A, 103, 2316, 10.1073/pnas.0508776103 · DOI · Paper page
  13. JK Lennerz, 2011, MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib, J Clin Oncol, 29, 4803, 10.1200/JCO.2011.35.4928 · DOI · Paper page
  14. PC Ma, 2008, Expression and mutational analysis of MET in human solid cancers, Genes Chromosomes Cancer, 47, 1025, 10.1002/gcc.20604 · DOI · Paper page
  15. LJ Herrera, 2005, The HGF receptor Met is overexpressed in esophageal adenocarcinoma, Neoplasia, 7, 75, 10.1593/neo.04367 · DOI
  16. A Sehdev, 2013, Gastroesophageal cancer: focus on epidemiology, classification, and staging, Discov Med, 16, 103
  17. DV Catenacci, 2011, Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence, Cancer Discov, 1, 573, 10.1158/2159-8290.CD-11-0175 · DOI · Paper page
  18. S Eathiraj, 2011, Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (Met) protein autophosphorylation by ARQ 197, J Biol Chem, 286, 20666, 10.1074/jbc.M110.213801 · DOI
  19. Oliner KS, Tang R, Anderson A, Lan Y, Iveson T, <etal>et al</etal>.. (2012) Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 30. · DOI
  20. BS Pan, 2010, MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated Met receptor, Cancer Res, 70, 1524, 10.1158/0008-5472.CAN-09-2541 · DOI
  21. KW Rickert, 2011, Structural basis for selective small molecule kinase inhibition of activated Met, J Biol Chem, 286, 11218, 10.1074/jbc.M110.204404 · DOI
  22. MA Shah, 2013, Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer, PLoS One, 8, e54014, 10.1371/journal.pone.0054014 · DOI · Paper page
  23. JP Eder, 2009, Novel therapeutic inhibitors of the Met signaling pathway in cancer, Clin Cancer Res, 15, 2207, 10.1158/1078-0432.CCR-08-1306 · DOI · Paper page
  24. LP Stabile, 2008, Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis, Mol Cancer Ther, 7, 1913, 10.1158/1535-7163.MCT-07-2169 · DOI
  25. Y Dai, 2010, BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro, Mol Cancer Ther, 9, 1554, 10.1158/1535-7163.MCT-10-0359 · doi:10.1158/1535-7163.mct-10-0359
  26. N Puri, 2007, A selective small molecule inhibitor of Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts, Cancer Res, 67, 3529, 10.1158/0008-5472.CAN-06-4416 · DOI
  27. Z Meng, 2011, Targeted mass spectrometry approaches for protein biomarker verification, J Proteomics, 74, 2650, 10.1016/j.jprot.2011.04.011 · DOI
  28. DC Liebler, 2013, Targeted quantitation of proteins by mass spectrometry, Biochemistry, 52, 3797, 10.1021/bi400110b · DOI · Paper page
  29. T Hembrough, 2013, Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue, J Mol Diagn, 15, 454, 10.1016/j.jmoldx.2013.03.002 · DOI
  30. T Hembrough, 2012, Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue, Clin Proteomics, 9, 5, 10.1186/1559-0275-9-5 · DOI
  31. J Prioleau, 1995, p53 antigen loss in stored paraffin slides, N Engl J Med, 332, 1521, 10.1056/NEJM199506013322217 · doi:10.1056/nejm199506013322217
  32. TW Jacobs, 1996, Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer, J Natl Cancer Inst, 88, 1054, 10.1093/jnci/88.15.1054 · doi:10.1093/jnci/88.15.1054
  33. M Mirlacher, 2004, Influence of slide aging on results of translational research studies using immunohistochemistry, Mod Pathol, 17, 1414, 10.1038/modpathol.3800208 · doi:10.1038/modpathol.3800208
  34. M Gry, 2009, Correlations between RNA and protein expression profiles in 23 human cell lines, BMC Genomics, 10, 365, 10.1186/1471-2164-10-365 · DOI · Paper page
  35. S von Ahlfen, 2007, Determinants of RNA quality from FFPE samples, PLoS One, 2, e1261, 10.1371/journal.pone.0001261 · DOI · Paper page
  36. G Sauter, 2003, Tissue microarrays in drug discovery, Nat Rev Drug Discov, 2, 962, 10.1038/nrd1254 · DOI · Paper page
  37. HE Lee, 2012, MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome, Br J Cancer, 107, 325, 10.1038/bjc.2012.237 · DOI
  38. Y Toiyama, 2012, Co-expression of hepatocyte growth factor and Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/Met signaling in gastric cancer, Int J Cancer, 130, 2912, 10.1002/ijc.26330 · DOI
  39. J Zhao, 2011, Up-regulated expression of Ezrin and Met proteins are related to the metastasis and prognosis of gastric carcinomas, Histol Histopathol, 26, 1111
  40. Catenacci DVT, Henderson L, Peng Xu, Rambo B, Liao WL, <etal>et al</etal>.. (2014) Towards personalized treatment for gastroesophageal adenocarcinoma (GEC): strategies to address tumor heterogeneity – PANGEA.; Abstr 66, 2014; San Francisco, CA. January 16–18. · doi:10.1200/jco.2014.32.3_suppl.66
  41. C Gomez-Martin, 2013, Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab, J Clin Oncol, 31, 4445, 10.1200/JCO.2013.48.9070 · DOI · Paper page
  42. DR Spigel, 2013, Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer, J Clin Oncol, 31, 4105, 10.1200/JCO.2012.47.4189 · DOI · Paper page
  43. Catenacci DVT XP, Henderson L, Liao WL, Burrows J, Hembrough T. (2012) Development of a quantitative gastroesophageal cancer selected reaction monitoring mass spectrometric multi-plex assay for use in FFPE tumor tissues. Poster Presentation at 24th EORTC NCI AACR Symposium, Abstr 561 December 7, 2012. Dublin, Ireland. · doi:10.1016/s0959-8049(12)72358-4
  44. Hembrough T, Thyparambil S, Henderson L, Rambo B, Cecchi F, <etal>et al</etal>.. (2014) Quantification of MET expression using Mass Spectrometry (MS): Assay Precision and Stability in FFPE Tumor Tissue; San Francisco, CA. January 16–18. · doi:10.1200/jco.2014.32.3_suppl.16
  45. T Stricker, 2011, Molecular profiling of cancer–the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic, Semin Oncol, 38, 173, 10.1053/j.seminoncol.2011.01.013 · DOI
  46. Khoury J, Catenacci DV (in press) Next-Generation companion diagnostics: promises, challenges, and solutions. Arch Pathol Lab Med 2014. · DOI
  47. G Athauda, 2006, Met ectodomain shedding rate correlates with malignant potential, Clin Cancer Res, 12, 4154, 10.1158/1078-0432.CCR-06-0250 · DOI
  48. N Archidiacono, 1995, Comparative mapping of human alphoid sequences in great apes, using fluorescence in situ hybridization, Genomics 1995 Jan 20, 25(2), 477

Cited by

Metadata

Authors
Catenacci, D. V. T., Liao, W.-L., Thyparambil, S., Henderson, L., Xu, P., Zhao, L., Rambo, B., Hart, J., Xiao, S.-Y., Bengali, K., Uzzell, J., Darfler, M., Krizman, D. B., Cecchi, F., Bottaro, D. P., Karrison, T., Veenstra, T. D., Hembrough, T., & Burrows, J.
Venue
PLoS ONE
Published
2014-07-01
Volume
9
Issue
7
Pages
e100586
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2156394972
Cited by
53
References
1
FWCI
2.45
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.